Took this from the coml website found as a link on the mgm website. Too bad coml does not update their own web as it would be easier to find. Also I notice that volume is picking up again.
The complete text of the DIAPRO POC·KIT System Business Plan can be downloaded from the attached file. To download the Business Plan, position the cursor over the file icon, right click on the mouse and select the "save" option.
The DIAPRO POC·KIT SystemTM (Patent Pending) Immunodiagnostic Test Platform
This Point-Of-Care Platform is design to diagnose, at the patent's bedside, diseases such as stroke, heart attack, kidney failure and breast cancer. Simply placing a finger-prick of the patient's blood on the DIAPRO BioChip carries out the test. The BioChip automatically separates and measures a predetermined volume of plasma, making it a RAPID FORMAT QUANTITATIVE TEST. This plasma volume is used to generate a calibration curve while, at the same time, allowing specific antibodies to capture a quantity of disease protein molecules. Every biochip is self-calibrating.
The BioChip is inserted into the electronic hand-held reader. The reader measures the concentrations of disease protein molecules, compares this value to the calibration curve and displays the resulting disease protein concentration. The concentration of disease protein is directly indicative of the disease severity in the patient. Early detection of the diseases such as stroke is critical for the patient. Early diagnosis results in immediate treatment thereby preventing destruction of tissue such as brain cells, leading to better patient recovery.
The DIAPRO BioChip is for single use and is disposable. The DIAPRO POC·KIT System provides a diagnostic result within minutes.
BREAKTHROUGH ADVANTAGES
Unlike other Point-Of-Care tests, the BioChip is fully quantitative and contains NO "chromatography" paper. The BioChip uses small volumes of test fluid, typically from 5-10 microlitres. In contrast, other tests need about 150 microlitres of test fluid. Each DIAPRO BioChip is self-calibrating, using a portion of the actual test fluid, e.g. plasma. Each BioChip is bar-coded for automatic identification in the reader.
The DIAPRO POC·KIT System Platform is designed to adapt immunodiagnostic tests. The DIAPRO BioChip can also test for more than one condition, provided that the requisite analysis components have been placed on the BioChip. More extensive analysis of data in the reader can also be carried out and this data may be transferred to other locations via digital transmission.
FIRST COMMERCIAL USE OF THE DIAPRO POC·KIT SYSTEM
The Platform is now being adapted to a proprietary STROKE TEST. The North American market requires more than 600,000 stroke tests each year.
THE DIAPRO POC·KIT SystemTM (Patent Pending)
This System PLATFORM has two major components:
A diagnostic and/or prognostic (DIAPRO) BioChip
A hand-held electronic reader
DESIGNED TO BE USED IN A POINT-OF-CARE RAPID FORMAT
PROPERTIES OF THE DIAPRO BioChipTM
Single use, disposable
Automatically separates plasma from whole blood
Full Quantitative
Uses minimal volume of test fluid e.g. human plasma
Use NOT bibulous components; "Paperless" device
Self calibrating, generates a Calibration Curve
May test for more than one medical condition
Bar coded for automatic Test identification
PROPERTIES OF THE POC·KITTM READER
Automatic biochip identification
Data analysis, including Neural Network Analysis and ROC plots
Data transmission, communication and digital protocols |
